Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1999-01-15
2000-07-11
Krass, Frederick
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514544, 514549, 424422, 424423, 424430, 600 29, 600 30, 600 31, 604264, 604275, 604285, 604288, 6048921, A01N 3712
Patent
active
060873965
ABSTRACT:
Oxybutynin chloride formulations having increased stability at body temperature, even at high concentrations. These formulations comprise oxybutynin chloride at a pH of between 3.0 and 5.0, and may include a buffer capable of providing adequate buffering capacity in this range. The OC solutions can be placed in an infuser device for treatment of bladder dysfunction.
REFERENCES:
patent: 4327725 (1982-05-01), Cortese et al.
patent: 4519801 (1985-05-01), Edgren
patent: 4612008 (1986-09-01), Wong et al.
patent: 4783337 (1988-11-01), Wong et al.
patent: 5082668 (1992-01-01), Wong et al.
patent: 5399359 (1995-03-01), Baichwal
patent: 5674895 (1997-10-01), Guittard et al.
Brendler, et al., Topical Oxybutynin Chloride for Relaxation of Dysfunctional Bladders, J. of Urology 141:1350-1352; 1989.
Bonney, et al., Topical Effect of Intravesical Oxybutynin, J. of Urology 150:1522-1525; 1993.
Conner, et al., Early Cystometrograms Can Predict the Response to Intravesical Instillation of Oxybutynin Chloride in Myelomeningocele Patients, J. of Urology 151:1045-1047; 1994.
Greenfield, et al., The Use of Intravesical Oxybutynin chloride in Children with Neurogenic Bladder, J. of Urology 146:532-534; (1991).
Kaplinsky, et al., Expanded Followup of Intravesical Oxybutynin Chloride Use in Children with Neurogenic Bladder, J. of Urology 156:753-756; (1996).
Madersbacher, M.D., et al., Control of Detrusor Hyperreflexia by the Intravesical Instillation of Oxybutynine Hydrochloride, Paraplegia 29:84-90; (1991).
Massad, et al., The Pharmacokinetics of Intravesical and Oral Oxybuytnin Chloride, J. of Urology 148:595-597 (1992).
Painter, et al., Long-Term Intravesical Oxybutynin Chloride Therapy in Children with Myelodysplasis, J. of Urology 156:1459-1462 (1996).
Palmer, et al., Complications of Intravesical Oxybutynin Chloride Therapy in the Pediatric Myelomeningocele Population, J. of Urology 157:638-640 (1997).
Prasad, et al., Intravesical Oxybutynin Chloride and Clean Intermittent Catheterisation in Patients with Neurogenic Vesical Dysfunction and Decreased Bladder Capacity, British J. of Urology 72:719-722 (1993).
Weese, M.D., et al., Intravesical Oxybutynin Chloride: Experience with 42 Patients, Urology 41(6):527-530; (1993).
United States Official Monographs 23:1127-1129; (1992).
Barion et al., Oxybutyninlosung zur Instillation in die Blase, Krankenhaus Pharmazie 18/4:171-172 (1997) English Abstract.
Buyse, et al., Intraesical Application of a Stable Oxybutynin Solution Improves Therapeutic Compliance and Acceptance in Children with Neurogenic Bladder Dysfunction, J. of Urology 160:1084-1087 (1998).
Yokoyama, et al., Urodynamic Effects of Intravesical Oxybutynin Chloride in Conscious Rats, J. of Urology 155:768-771 (1996).
Nunn, et al., Buffer Helps Stabilise Oxybutynin, database Embase "Online!" Abstract, (1994).
Krass Frederick
Situs Corporation
LandOfFree
Oxybutynin formulations and method of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxybutynin formulations and method of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxybutynin formulations and method of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542868